A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

Start Date01 May 2026

Sponsor / Collaborator

Enlivex Ltd.

[+1]

NCT06748651

/ RecruitingPhase 1IIT

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Temporomandibular Joint Osteoarthritis (TMJ-OA)

This study is a single center trial to assess the safety and initial efficacy of intra-articular administration of Allocetra to patients with Temporomandibular Joint Osteoarthritis (TMJ-OA)

Start Date15 Dec 2024

Sponsor / Collaborator

Sheba Medical Center

[+1]

NCT06522035

/ TerminatedPhase 1

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

Start Date01 Aug 2024

Sponsor / Collaborator

Enlivex Ltd.

100 Clinical Results associated with Allocetra

100 Translational Medicine associated with Allocetra

100 Patents (Medical) associated with Allocetra

Literatures (Medical) associated with Allocetra

19 Aug 2024·MILITARY MEDICINE

Apoptotic Cell–Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock

Article

Author: Lutsker, Maya ; Kolben, Yotam ; Mevorach, Dror ; Wagnert-Avraham, Linn ; Aliev, Emil ; Kenig, Ariel ; Kessler, Asa ; Nachman, Dean

ABSTRACT:

Introduction:

Many trauma patients die from hemorrhagic shock in the military and civilian settings. Although two-thirds of hemorrhagic shock victims die of reasons other than exsanguination, such as the consequent cytokine storm, anti-inflammatory therapies failed to be utilized. Apoptotic cell–based treatments enhance innate ability to exert systemic immunomodulation as demonstrated in several clinical applications and hence might present a novel approach in hemorrhagic shock treatment.

Materials and Methods:

Twenty-two rats underwent a pressure-controlled hemorrhagic shock model and followed up for 24 hours. An infusion of apoptotic cells (Allocetra-OTS, Enlivex Therapeutics Ltd, Nes Ziona, Israel) was administered to the treatment group. Hemodynamics, blood counts, biochemistry findings, and cytokine profile were compared to a saline-resuscitated control group.

Results:

The treatment group’s mean arterial pressure decreased from 94.8 mmHg to 28.2 mmHg, resulting in an 8.13 mg/dL increase in lactate and a 1.9 g/L decrease in hemoglobin, similar to the control group. White blood cells and platelets decreased more profoundly in the treatment group. A similar cytokine profile after 24 hours was markedly attenuated in the treatment group 2 hours after bleeding. Levels of pro-inflammatory cytokines such as interleukin (IL)-1a (28.4 pg/mL vs. 179.1 pg/mL), IL-1b (47.4 pg/mL vs. 103.9 pg/mL), IL-6 (526.2 pg/mL vs. 3492 pg/mL), interferon γ (11.4 pg/mL vs. 427.9 pg/mL), and tumor necrosis factor α (19.0 pg/mL vs. 31.7 pg/mL) were profoundly lower in the treatment group.

Conclusion:

In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell–based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.

Frontiers in immunologyQ2 · MEDICINE

Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis– A Phase Ib Clinical Trial

Q2 · MEDICINE

ArticleOA

Author: El-Amore, Raja ; Abutbul, Avraham ; Falah, Batla ; Reicher, Barak ; van Heerden, Peter Vernon ; Zlotnick, Eitan ; Nama, Ahmad ; Mevorach, Dror ; Zimro, Sebastian ; Shabat, Yehudit ; Sviri, Sigal

Background:

Sepsis has no proven specific pharmacologic treatment and reported mortality ranges from 30%–45%. The primary aim of this phase IB study was to determine the safety profile of Allocetra™-OTS (early apoptotic cell) infusion in subjects presenting to the emergency room with sepsis. The secondary aims were to measure organ dysfunction, intensive care unit (ICU) and hospital stays, and mortality. Exploratory endpoints included measuring immune modulator agents to elucidate the mechanism of action.

Methods:

Ten patients presenting to the emergency room at the Hadassah Medical Center with sepsis were enrolled in this phase Ib clinical study. Enrolled patients were males and females aged 51–83 years, who had a Sequential Organ Failure Assessment (SOFA) score ≥2 above baseline and were septic due to presumed infection. Allocetra™-OTS was administered as a single dose (day +1) or in two doses of 140×106 cells/kg on (day +1 and +3), following initiation of standard-of-care (SOC) treatment for septic patients. Safety was evaluated by serious adverse events (SAEs) and adverse events (AEs). Organ dysfunction, ICU and hospital stays, and mortality, were compared to historical controls. Immune modulator agents were measured using Luminex® multiplex analysis.

Results:

All 10 patients had mild-to-moderate sepsis with SOFA scores ranging from 2–6 upon entering the study. No SAEs and no related AEs were reported. All 10 study subjects survived, while matched historical controls had a mortality rate of 27%. The study subjects exhibited rapid resolution of organ dysfunction and had significantly shorter ICU stays compared to matched historical controls (p<0.0001). All patients had both elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that gradually decreased following treatment.

Conclusion:

Administration of apoptotic cells to patients with mild-to-moderate sepsis was safe and had a significant immuno-modulating effect, leading to early resolution of the cytokine storm.

Clinical Trial Registration:

ClinicalTrials.gov Identifier: NCT03925857. (https://clinicaltrials.gov/ct2/show/study/NCT03925857).

Pharmaceutics

Safety of Repeated Administration of Xenogeneic Human Apoptotic State (Allocetra-OTS) in Sprague Dawley Rats

Article

Author: Brami, Meital ; Hershkovitz, Oren ; Hershkovitz, Liat ; Sarig, Hadar ; Mevorach, Dror ; Amor-Baroukh, Veronique ; Reicher, Barak ; Levy, Ronnie ; Souli, Einat ; Nyska, Abraham ; Ankri, Chen

Apoptotic cells possess immunomodulatory effects that can be utilized to treat imbalanced immune conditions. Information on the preclinical safety of such treatment is sparse. In this study, the safety of apoptotic cells (Allocetra-OTS) was assessed in a GLP toxicological study on Sprague Dawley rats. Three doses of Allocetra-OTS or vehicle were administered intravenously (IV) for 3 consecutive days. Animals in the main study were sacrificed on day 4, while animals from the recovery groups were kept for 14 or 28 days. Allocetra-OTS was well tolerated, and no adverse effects were observed in terms of body weight, clinical signs, food consumption, or ophthalmologic observation. Thus, the No Observed Adverse Effect Level (NOAEL) dose was determined as the highest dose administered. An observed elevation in immune cells was suspected to be due to Allocetra-OTS, similarly to other clinical chemistry parameters; however, it was resolved in the recovery phases. Splenomegaly and dose-related extramedullary hematopoiesis (EMH) in the red pulp were observed, with no adverse events, and were considered to be a normal and expected reaction following the IV administration of cell-based therapies. In conclusion, under the conditions of this study, Allocetra-OTS was concluded to be safe, further supporting its potential candidacy for clinical studies.

124

News (Medical) associated with Allocetra

04 Aug 2026

·www.globenewswire.com

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time to provide investors with additional detail on the Company’s recently announced private placement (the “Transaction”), the status and strategy of its RAIN treasury, and recent clinical progress for Allocetra™. Webinar Agenda Company management will provide an update across three areas: ● Private Placement & Treasury Strategy: the rationale for the Transaction, the Company’s intended use of proceeds, and how the Transaction fits within the Company’s long-term treasury strategy built around the Rain protocol ● Rain Protocol Update: current status of the Company’s treasury portfolio and a review of recent milestones and the growth roadmap provided by the Rain Foundation ● Clinical Update – Allocetra™: progress of the ongoing Phase 2b trial in age-related knee osteoarthritis, and the recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Allocetra™ in the treatment of symptomatic knee osteoarthritis in patients aged 64 and older Webinar Details Date/Time: Thursday, July 30, 2026, at 10:00 AM Eastern Time Registration: https://www.redchip.com/webinar/ENLV/82414254076 This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. ABOUT ENLIVEX Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits and timing of the completion of the proposed Transaction and related transactions and the intended use of proceeds from the Transaction; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results, including with respect to the RMAT-designated Allocetra™ program; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, Allocetra™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Transaction and the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; the risk that RMAT designation does not guarantee a faster development timeline, FDA approval, or that all anticipated benefits of the designation will be realized; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Ltd.shachar@enlivex.com

Phase 2Immunotherapy

30 Jul 2026

·www.globenewswire.com

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. Trading volume on the Rain protocol reached $860 million, and experienced a substantial increase of 622% between the trading volume of June 2026 vs July 2026. According to the Rain Foundation, the target trading volumes on the protocol are expected to increase substantially to $1.3 billion in 2027, $12 billion in 2028, and $33 billion in 2029. At these trading levels, gross fees received by the Rain Foundation are expected to be $49 million, $436 million and $1.2 billion, and the net fees allocated to buy-and-burn the RAIN token would be $24 million, $216 million and $600 million, in 2027, 2028 and 2029, respectively. Mr. Shai Novik, Executive Chairman of Enlivex commented, “Prediction markets could reach $1 trillion in annual trading volume by 20302, according to various analysts. We are pleased with the progress of the Rain protocol and believe that it has the potential to solidify itself as the primary decentralized prediction market. We hope that as this trend continues, the Enlivex RAIN treasury portfolio will be viewed and valued differently by investors.” The updated unaudited mark-to-market treasury metrics are publicly available on the Company's website at https://enlivex.com/dashboard/. Detailed information about the RAIN token’s listing on various exchanges, daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/ . About Enlivex Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-looking statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. Enlivex contact Shachar ShlosbergerCFOEnlivex Ltd.shachar@enlivex.com 1 Data provided by the Rain Foundation2 Source: Industry analysis by Eilers and Krejcik Gaming (EKG), December 2025

Immunotherapy

28 Jul 2026

·www.globenewswire.com

Enlivex Announces $400,000,000 Private Placement

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) at a price of $5.00 per share for subscription amounts funded in U.S. dollars, USDT or USD Coin and $6.00 per share for subscription amounts funded in RAIN tokens, the $5.00 price representing a premium of 17.4% and the $6.00 price representing a premium of 40.8%, in each case to the closing price of the ordinary shares on July 27, 2026, for expected aggregate gross proceeds of approximately $400,000,000 (funded in U.S. dollars, USDT, USD Coin, RAIN tokens or a combination thereof), before deducting offering expenses (the "Transaction"). The investor has elected to fund the purchase price using RAIN tokens, which election may be changed at any time prior to closing. Enlivex intends to use net proceeds from the private placement in furtherance of its treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum, while continuing to advance Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The securities purchase agreement also provides the Company with the right, but not the obligation, exercisable in its sole discretion at any time and from time to time during the 36-month period following the closing of the Transaction, to require the investor in the Transaction to purchase up to an additional $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) on the same pricing terms described above. The Company has no obligation to exercise this right, and the investor has no right to require the Company to do so. The closing of the Transaction is subject to approval by the Company's shareholders of the issuance of the securities and the ordinary shares issuable pursuant to the Company's put right described above for purposes of Nasdaq Listing Rules 5635(a) and 5635(b) and Section 274 of the Israeli Companies Law. The Company expects to consummate the Transaction promptly following receipt of such shareholder approval. Greenberg Traurig P.A. and FISCHER (FBC & Co.) serve as legal counsels to Enlivex. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT ENLIVEX Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits and timing of the completion of the proposed Transaction and related transactions and the intended use of proceeds from the Transaction; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Transaction and the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, Ltd.shachar@enlivex.com

Immunotherapy

100 Deals associated with Allocetra

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	Israel	Enlivex Ltd.	26 Jan 2024
Advanced Malignant Solid Neoplasm	Phase 2	Israel	Enlivex Ltd.	15 Nov 2022
Advanced Malignant Solid Neoplasm	Phase 2	Spain	Enlivex Ltd.	15 Nov 2022
Neoplasm Metastasis	Phase 2	Israel	Enlivex Ltd.	29 Jun 2022
Secondary malignant neoplasm of peritoneum	Phase 2	Israel	Enlivex Ltd.	29 Jun 2022
Respiratory Distress Syndrome, Acute	Phase 2	Israel	Enlivex Ltd.	01 Sep 2021
Cholangitis	Phase 2	Belgium	Enlivex Ltd.	30 Nov 2020
Cholangitis	Phase 2	France	Enlivex Ltd.	30 Nov 2020
Cholangitis	Phase 2	Israel	Enlivex Ltd.	30 Nov 2020
Cholangitis	Phase 2	Netherlands	Enlivex Ltd.	30 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06233474 (ENX-CL-05-001, EULAR2026)	Phase 2	Osteoarthritis, Knee	134	Allocetra	gylqskvfls(celdfrkthe) = ffrxcoboyo jlfruegmri (wtqmviueiv ) View more	Positive	11 Jun 2026
				Placebo	nsqppcgwye(dedihpinjq) = uenunsvatu mgyfpncxgq (horfsocvqh )
NCT06233474 (ENX-CL-05-001 \| ENXCL05001, GlobeNewswire) Manual	Phase 2	Osteoarthritis, Knee	-	Allocetra	eqoztgifbi(eomdrjlezx) = zbipiwycra saxukuixsr (dhutwkoxjl ) View more	Positive	24 Nov 2025
				Placebo	eqoztgifbi(eomdrjlezx) = ghohtgukar saxukuixsr (dhutwkoxjl ) View more
NCT06233474 (ENXCL05001, GlobeNewswire)	Phase 1/2	Osteoarthritis \| Osteoarthritis, Knee	130	AllocetraOTS	dfympemhgr(ysuetlkujd): Difference (%) = 26 View more	Positive	18 Aug 2025
				placebo
EULAR2025	Phase 1/2	Osteoarthritis, Knee	15	AllocetraTM	onwxrhbacc(xhypcjjytj) = xibihiiwes plivflhfej (bpzymxuaqy, 35.1 - 69.7) View more	Positive	11 Jun 2025
NCT06233474 (GlobeNewswire) Manual	Phase 1/2	Osteoarthritis, Knee	12	Allocetra	nhdxsngabm(sjlckgoosc) = hsazvqrapt ibkhdoczid (aeqvrakxgf ) View more	Positive	03 Dec 2024
NCT06233474 (Biospace) Manual	Phase 1/2	Osteoarthritis, Knee	9	Allocetra	hpxdjqlxyv(fpjzdaqvap) = nnsgexvkib rjxemmxykq (jmvvuzwnyt ) View more	Positive	17 Jun 2024
NCT04612413 (GlobeNewswire) Manual	Phase 2	Sepsis	-	Allocetra	senbkgtirr(hxbuzflecb) = nzxryhjpsp minvjmwwnt (nsakfhdwey ) View more	Positive	11 Apr 2024
NCT03925857 (P-SOFA-1, Pubmed \| Front Immunol) Manual	Phase 1	Sepsis	10	Allocetra™-OTS	vbtavydocn(ytvieqlvxj) = No SAEs were reported. ejwluuzbul (dtfcwuzebt ) View more	Positive	30 Sep 2021
				historical controls
NCT04590053 (GlobeNewswire) Manual	Phase 2	COVID-19	16	Allocetra	fhtxjpdalu(qxmtjnkivt) = gmxuunxopi mhmhajtwax (yqzxicioum ) View more	Positive	03 Feb 2021
NCT03925857 (P-SOFA-1, GlobeNewswire) Manual	Phase 1	Sepsis	47	Allocetra	nqvzotkaip(aabzjhfdqm) = cefodnhatu quujetgsrd (tyldvvrpuh ) View more	Positive	18 Mar 2020
				Standard of Care	hgujapudmb(frrrfokjfp) = opggbufxtz mutmfcyzrt (omeicvohip ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis